Biomarkers of residual disease at surgery identify which triple-negative breast cancer patients already treated with neoadjuvant therapy will do well and which will do poorly over the next 2 years.
Medscape Medical News …read more
Biomarkers of residual disease at surgery identify which triple-negative breast cancer patients already treated with neoadjuvant therapy will do well and which will do poorly over the next 2 years.
Medscape Medical News …read more